{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:49:56Z","timestamp":1789235396305,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ekir.2025.01.042","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T17:05:01Z","timestamp":1738602301000},"page":"1188-1195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study"],"prefix":"10.1016","volume":"10","author":[{"given":"Caroline","family":"Arches","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Jalal-Eddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Titeca-Beauport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lobbedez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Zaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Masset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"El Karoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Brenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Sakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Peiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Joher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.01.042_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome\u2013associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.042_bib2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2025.01.042_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1055\/s-0033-1343887","article-title":"Thrombosis in nephrotic syndrome","volume":"39","author":"Barbano","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ekir.2025.01.042_bib4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.01.042_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2007.10.030","article-title":"Clinical characteristics and long-term follow-up of patients with renal vein thrombosis","volume":"51","author":"Wysokinski","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.01.042_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2215\/CJN.05250419","article-title":"Prophylactic anticoagulation in adult patients with nephrotic syndrome","volume":"15","author":"Gordon-Cappitelli","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.042_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.01.042_bib8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.01.042_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.01.042_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41397-024-00329-y","article-title":"Being precise with anticoagulation to reduce adverse drug reactions: Are we there yet?","volume":"24","author":"Cross","year":"2024","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ekir.2025.01.042_bib11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis","volume":"12","author":"Van Der Hulle","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.01.042_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12875-024-02314-7","article-title":"European expert consensus recommendations on the primary care use of direct oral anticoagulants in patients with venous thromboembolism","volume":"25","author":"Patrice","year":"2024","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.ekir.2025.01.042_bib13","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2025.01.042_bib14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.kint.2019.11.027","article-title":"Role of direct oral anticoagulants in patients with kidney disease","volume":"97","author":"Derebail","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.01.042_bib15","first-page":"739","article-title":"Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ekir.2025.01.042_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12882-022-02929-x","article-title":"Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: A report of 21 cases","volume":"23","author":"Kelddal","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.01.042_bib17","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1055\/a-1920-6224","article-title":"Apixaban prophylactic anticoagulation in patients with nephrotic syndrome","volume":"06","author":"Van Meerhaeghe","year":"2022","journal-title":"TH Open"},{"key":"10.1016\/j.ekir.2025.01.042_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/10600280221129348","article-title":"Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in patients with nephrotic syndrome: A retrospective cohort study","volume":"57","author":"Tijani","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2025.01.042_bib19","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","article-title":"Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome","volume":"3","author":"Sexton","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.01.042_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ekir.2025.01.042_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ekir.2019.12.001","article-title":"A\u00a0systematic review of prophylactic anticoagulation in nephrotic syndrome","volume":"5","author":"Lin","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.01.042_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.01.042_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.01.042_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.01.042_bib25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non\u2013vitamin K Oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2025.01.042_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.716224","article-title":"Cost-effectiveness analysis of direct oral anticoagulants versus vitamin K antagonists for venous thromboembolism in china","volume":"12","author":"Sun","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2025.01.042_bib27","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2025.01.042_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of Rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2025.01.042_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"Chang","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2025.01.042_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s11239-020-02092-w","article-title":"Albumin and bleed risk in Rivaroxaban treated patients","volume":"50","author":"Wojakowski","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.ekir.2025.01.042_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2022.09.011","article-title":"Pharmacokinetics and pharmacodynamics of Apixaban in nephrotic syndrome: Findings from a Phase 1a trial","volume":"81","author":"Derebail","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.01.042_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ndt\/gfw227","article-title":"Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome","volume":"32","author":"Gyamlani","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.042_bib33","article-title":"Risk Factors of Venous Thromboembolism in Patients With Nephrotic Syndrome: a Retrospective Cohort Study","volume":"13","author":"Shinkawa","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.042_bib34","first-page":"5955","article-title":"Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios","volume":"12","author":"Luc\u00e0","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ekir.2025.01.042_bib35","first-page":"37","article-title":"Pharmacogenetics of direct oral anticoagulants: A systematic review","volume":"11","author":"Raymond","year":"2021","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.ekir.2025.01.042_bib36","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/phar.1597","article-title":"Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy","volume":"35","author":"Lauffenburger","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ekir.2025.01.042_bib37","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.01.042_bib38","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:01:05Z","timestamp":1747285265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2468024925000671"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.01.042","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.02.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}